Abstract
SARS-CoV-2 can be disinfected using ultraviolet-C (UVC) light. For effective inactivation strategies, design and implementation, knowledge of UVC wavelength sensitivity, and disinfection rate of the relevant pathogen are required. This study aimed to determine the inactivation profile of SARS-CoV-2 using UVC irradiation with different wavelengths. Specifically, the study determined dosage, inactivation levels, and wavelength sensitivity of SARS-CoV-2. Assessment of SARS-CoV-2 (isolate USA/WA1-2020) inactivation at peak wavelengths of 259, 268, 270, 275 and 280 nm was performed using a plaque assay method. A UVC dose of 3.1 mJ/cm2 using 259 and 268 nm arrays yielded log reduction values (LRV) of 2.32 and 2.44, respectively. With a dose of 5 mJ/cm2, arrays of peak wavelengths at 259 and 268 nm obtained similar inactivation levels (LRV 2.97 and 2.80 respectively). The arrays of longer wavelength (270, 275 and 280 nm), demonstrated lower performances (≤LRV 2.0) when applying an irradiation dose of 5 mJ/cm2. Additional study with the 268 nm array revealed that a dose of 6.25 mJ/cm2 is enough to obtain a LRV of 3. These results suggest that 259 and 268 nm are the most efficient wavelengths for SARS-CoV-2 inactivation compared to longer UVC wavelengths, allowing the calculation of disinfection systems efficacy.
- COVID-19
- Inactivation
- Public health
- SARS-CoV-2
- UVC
- Wavelength sensitivity
Competing Interest Statement
R. M. Mariita, A. C. W. Miller and R. V. Randive work for Crystal IS, an Asahi Kasei company that manufactures UVC LEDs. L. G. A. McKay, N. Storm, and A. Griffiths have no competing interests to declare.
Funding Statement
This research did not receive any specific grant from funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No human or animal subjects were used in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Original SARS-CoV-2 disinfection data and laboratory report is available upon reasonable request. Spectral confirmation data is available via https://doi.org/10.6084/m9.figshare.14884743.v1
